$HRTX
Heron Therapeutics Inc

2020 Q4 Form 10-K Financial Statement

#000156459021007841 Filed on February 24, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $20.61M $20.00M $22.70M
YoY Change -41.27% -53.08% -38.08%
Cost Of Revenue $9.392M $7.170M $9.005M
YoY Change -40.83% -58.3% -33.73%
Gross Profit $11.21M $12.80M $13.66M
YoY Change -41.63% -49.68% -40.78%
Gross Profit Margin 54.42% 63.98% 60.19%
Selling, General & Admin $28.06M $22.00M $25.41M
YoY Change -7.39% -13.99% -23.99%
% of Gross Profit 250.21% 171.92% 185.96%
Research & Development $44.45M $49.18M $44.00M
YoY Change -7.92% 41.7% 6.23%
% of Gross Profit 396.44% 384.38% 322.07%
Depreciation & Amortization $710.0K $770.0K $750.0K
YoY Change 26.79% 48.08% 53.06%
% of Gross Profit 6.33% 6.02% 5.49%
Operating Expenses $72.51M $71.18M $69.41M
YoY Change -7.72% 18.08% -7.27%
Operating Profit -$61.30M -$58.38M -$55.75M
YoY Change 3.26% 67.51% 7.67%
Interest Expense $160.0K $560.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$985.0K $156.0K $559.0K
YoY Change -168.31% -87.6% -64.1%
Pretax Income -$62.28M -$58.23M -$55.19M
YoY Change 7.53% 73.3% 9.9%
Income Tax
% Of Pretax Income
Net Earnings -$62.28M -$58.23M -$55.19M
YoY Change 7.53% 73.32% 9.89%
Net Earnings / Revenue -302.26% -291.14% -243.13%
Basic Earnings Per Share
Diluted Earnings Per Share -$683.8K -$640.9K -$608.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $208.5M $258.1M $300.8M
YoY Change -46.67% 0.7% 8.99%
Cash & Equivalents $105.1M $95.14M $80.73M
Short-Term Investments $103.4M $163.0M $220.1M
Other Short-Term Assets $22.00M $16.40M $13.10M
YoY Change -5.17% -1.8% 50.57%
Inventory $41.91M $42.75M $41.44M
Prepaid Expenses $19.46M
Receivables $41.85M $33.70M $37.50M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $314.2M $351.0M $392.9M
YoY Change -34.41% -3.6% 3.18%
LONG-TERM ASSETS
Property, Plant & Equipment $22.74M $38.70M $39.50M
YoY Change 15.9% 35.31% 29.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $346.0K $300.0K $300.0K
YoY Change 0.0% 18.11% 0.0%
Total Long-Term Assets $39.36M $39.00M $39.80M
YoY Change 16.73% 35.13% 28.8%
TOTAL ASSETS
Total Short-Term Assets $314.2M $351.0M $392.9M
Total Long-Term Assets $39.36M $39.00M $39.80M
Total Assets $353.6M $390.0M $432.7M
YoY Change -31.05% -0.75% 5.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $525.0K $12.10M $18.50M
YoY Change -80.96% 643.7% 131.25%
Accrued Expenses $94.90M $78.90M $67.90M
YoY Change 7.47% -12.14% -17.2%
Deferred Revenue
YoY Change
Short-Term Debt $7.100M $6.600M $6.300M
YoY Change 26.79% 22.22% 23.53%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $102.5M $97.60M $92.70M
YoY Change 6.0% 0.93% -2.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $14.60M $15.30M $16.00M
YoY Change 19.67% 41.67% 41.59%
Total Long-Term Liabilities $14.60M $15.30M $16.00M
YoY Change 19.67% 41.67% 41.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $102.5M $97.60M $92.70M
Total Long-Term Liabilities $14.60M $15.30M $16.00M
Total Liabilities $117.1M $112.9M $108.7M
YoY Change 7.45% 5.0% 2.25%
SHAREHOLDERS EQUITY
Retained Earnings -$1.393B
YoY Change 19.5%
Common Stock $913.0K
YoY Change 1.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $236.5M $277.1M $324.1M
YoY Change
Total Liabilities & Shareholders Equity $353.6M $390.0M $432.7M
YoY Change -31.05% -0.75% 5.11%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$62.28M -$58.23M -$55.19M
YoY Change 7.53% 73.32% 9.89%
Depreciation, Depletion And Amortization $710.0K $770.0K $750.0K
YoY Change 26.79% 48.08% 53.06%
Cash From Operating Activities -$52.55M -$42.06M -$57.27M
YoY Change 94.77% 65.14% 147.81%
INVESTING ACTIVITIES
Capital Expenditures -$2.490M -$630.0K -$750.0K
YoY Change -36.15% -160.0% -65.28%
Acquisitions
YoY Change
Other Investing Activities $59.28M $56.58M $33.16M
YoY Change -148.41% 105.15% -24.64%
Cash From Investing Activities $56.79M $55.95M $32.40M
YoY Change -144.94% 95.42% -22.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.770M 520.0K 2.310M
YoY Change -96.51% -86.7% -78.71%
NET CHANGE
Cash From Operating Activities -52.55M -42.06M -57.27M
Cash From Investing Activities 56.79M 55.95M 32.40M
Cash From Financing Activities 5.770M 520.0K 2.310M
Net Change In Cash 10.01M 14.41M -22.56M
YoY Change -15.1% 103.82% -176.27%
FREE CASH FLOW
Cash From Operating Activities -$52.55M -$42.06M -$57.27M
Capital Expenditures -$2.490M -$630.0K -$750.0K
Free Cash Flow -$50.06M -$41.43M -$56.52M
YoY Change 116.9% 56.22% 169.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-33221
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-2875566
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
4242 CAMPUS POINT COURT
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 200
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
SAN DIEGO
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2020 dei City Area Code
CityAreaCode
858
CY2020 dei Local Phone Number
LocalPhoneNumber
251-4400
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28369000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
36535000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
88600000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
146000000.0
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
27939000
CY2020Q1 hrtx Period Of Income Taxes Receivable Net Operating Loss Cares Act
PeriodOfIncomeTaxesReceivableNetOperatingLossCARESAct
P5Y
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2385000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7400000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
1300000000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y2M15D
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-178840000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178917000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
370160000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2317000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33367000
CY2019Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
34614000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13597000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15248000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28369000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
36535000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2997000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71898000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
319074000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39879000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1926000
CY2020Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
7053000
CY2019Q4 us-gaap Inventory Net
InventoryNet
24968000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23245000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
479064000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19618000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16277000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13754000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
346000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
346000
CY2020Q4 us-gaap Assets
Assets
353556000
CY2019Q4 us-gaap Assets
Assets
512782000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
525000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2758000
CY2020Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
49962000
CY2019Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
5624000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
102503000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
96705000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14561000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12242000
CY2020Q4 us-gaap Liabilities
Liabilities
117064000
CY2019Q4 us-gaap Liabilities
Liabilities
108947000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91310000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91310000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90304000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90304000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
913000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
903000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1628070000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1568317000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
257000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
85000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1392748000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1165470000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
236492000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
403835000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
353556000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
512782000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
88638000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
145968000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
77474000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36189000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
61619000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27512000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
174533000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
167382000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
140032000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42226000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37897000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29263000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
63853000
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
89764000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
64604000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
316801000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
356662000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
261411000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-228163000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-210694000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-183937000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
3633000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
7259000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
5965000
CY2020 us-gaap Interest Expense
InterestExpense
1901000
CY2019 us-gaap Interest Expense
InterestExpense
1472000
CY2018 us-gaap Interest Expense
InterestExpense
2672000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-847000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
158000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1804000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
885000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5945000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5097000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-227278000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-204749000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-178840000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
172000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
172000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-227106000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-204577000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178917000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.50
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.50
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.44
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90774000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
81779000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73193000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
363128000
CY2018 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
392000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1179000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18301000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
162151000
CY2019 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
416000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2109000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22164000
CY2019 hrtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51411000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-204749000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
172000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-204577000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
403835000
CY2020 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
440000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6759000
CY2020 hrtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
26000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50218000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
172000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-227106000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
236492000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
51411000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-24773000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
22778000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
16937000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-204749000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-178840000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1295000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12052000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7482000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-14105000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1906000
CY2019 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
10144000
CY2018 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
-3614000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1851000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
4537000
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
14941000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-191805000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
33367000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2044000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1513000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1050000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
890000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3730000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3412000
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
8000
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
847000
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
107000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
72000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-62000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-29000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
497104000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
227700000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9171000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2317000
CY2020 hrtx Proceeds From Conversion Of Convertible Notes Payable
ProceedsFromConversionOfConvertibleNotesPayable
26000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1000
CY2019Q4 hrtx Available For Sale Securities Debt Securities Current Contractual Maturities Of Three Months To One Year
AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesOfThreeMonthsToOneYear
279700000
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2018 hrtx Cumulative Effect Of Adoption Of New Accounting Standard
CumulativeEffectOfAdoptionOfNewAccountingStandard
1574000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Concentration of Credit Risk</span></p> <p style="margin-top:6pt;line-height:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits may be in excess of insured limits. We may also invest our excess cash in money market funds, U.S. government and agencies, </span></p> <p style="margin-top:6pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></p> <p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI and SUSTOL are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers (collectively, “Customers”) that resell to healthcare providers and hospitals, the end users of CINVANTI and SUSTOL. </p> <p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our net product sales:</p> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Product</p> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div>
CY2020 hrtx Transfers Among Fair Value Hierarchy Levels Amount
TransfersAmongFairValueHierarchyLevelsAmount
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
55900000
CY2020Q4 hrtx Available For Sale Securities Debt Securities Current Contractual Maturities Of Three Months To One Year
AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesOfThreeMonthsToOneYear
103400000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
15000000.0
CY2019Q4 hrtx Available For Sale Securities Debt Securities With Contractual Maturities After One Year
AvailableForSaleSecuritiesDebtSecuritiesWithContractualMaturitiesAfterOneYear
39400000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
103096000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
257000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
103353000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
318989000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
85000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
319074000
CY2020 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
172000
CY2019 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
172000
CY2018 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-77000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1575955
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7742000
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
104000
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
310000
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
244000
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
544000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
18994000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6847000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
16064000
CY2020Q4 us-gaap Inventory Net
InventoryNet
41905000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33609000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27643000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10872000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8025000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22737000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19618000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2800000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2000000.0
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1500000
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
14100000
CY2019Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
13500000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1691000
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3047000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
8479000
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
9545000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
3427000
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2656000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13597000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15248000
CY2020Q4 hrtx Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
24571000
CY2019Q4 hrtx Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
27939000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3450000
CY2020Q4 hrtx Employee Stock Purchase Plan Available For Issuance
EmployeeStockPurchasePlanAvailableForIssuance
176250
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
220164
CY2020Q4 hrtx Common Stock Underlying Convertible Notes Outstanding
CommonStockUnderlyingConvertibleNotesOutstanding
9510208
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
602741
CY2020 hrtx Valuation Allowances And Reserves Provisions
ValuationAllowancesAndReservesProvisions
119065000
CY2020 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
-122433000
CY2020Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
24571000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
3942000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
4058000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
4178000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
4274000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
4379000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
20831000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3273000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
17558000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
3900000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
3100000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
3200000
CY2020Q4 us-gaap Restructuring Charges
RestructuringCharges
5600000
CY2020 us-gaap Restructuring Charges
RestructuringCharges
5600000
CY2011Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4300000
CY2020 hrtx Debt Instrument Convertible Number Shares Of Equity Instruments
DebtInstrumentConvertibleNumberSharesOfEquityInstruments
9500000
CY2018Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
168700000
CY2018Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
194400000
CY2019Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
162200000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18912529
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
30997847
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3200
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
25000.0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
69100
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
56300
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10237202
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.74
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7436379
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.02
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6523093
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.83
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
18179553
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
19.58
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
15962432
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.31
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14449017
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.11
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
18912529
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
19.59
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
10237202
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
18.74
CY2020Q4 hrtx Share Based Compensation Shares Authorized Under Stock Option And Other Than Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionAndOtherThanOptionPlansExercisePriceRangeNumberOfOutstandingOptions
19515270
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50218000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51411000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33367000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
116100000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-47728000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-42997000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-37557000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-8218000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-9823000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-6527000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4327000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4855000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4775000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
4675000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q1 hrtx Suspension Of Taxable Income Limitation Percentage For Operating Loss Carryforward
SuspensionOfTaxableIncomeLimitationPercentageForOperatingLossCarryforward
0.80
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2906000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-2059000
CY2020 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
1455000
CY2019 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
4720000
CY2018 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
901000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
53621000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
49479000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
50834000
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
522000
CY2019 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
570000
CY2018 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-817000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
251971000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
210301000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
49683000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
42490000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
20211000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
15628000
CY2020Q4 hrtx Deferred Tax Assets Tax Lease Liabilities
DeferredTaxAssetsTaxLeaseLiabilities
4330000
CY2019Q4 hrtx Deferred Tax Assets Tax Lease Liabilities
DeferredTaxAssetsTaxLeaseLiabilities
3487000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3777000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3818000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
329972000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
275724000
CY2020Q4 hrtx Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
4014000
CY2019Q4 hrtx Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
3385000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4014000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3385000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
325958000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
272339000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4784000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2385000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
120000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
341000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
147000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2281000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2252000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2265000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7406000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4784000
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2020 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
8550
CY2019 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
8400
CY2018 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
8250
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1100000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000.0
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
25400000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
22668000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19965000
CY2020Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20605000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10622000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9005000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7170000
CY2020Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9392000
CY2020Q1 us-gaap Gross Profit
GrossProfit
14778000
CY2020Q2 us-gaap Gross Profit
GrossProfit
13663000
CY2020Q3 us-gaap Gross Profit
GrossProfit
12795000
CY2020Q4 us-gaap Gross Profit
GrossProfit
11213000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36894000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44004000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49182000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44453000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10422000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9819000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9482000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12503000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20196000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15589000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12515000
CY2020Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15553000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
559000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
156000
CY2020Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-985000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-51579000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-55190000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-58228000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-62281000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31602000
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
36659000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
42624000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41425000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34708000
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48277000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9648000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9778000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-52734000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55749000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-58384000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-61296000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1155000
CY2019Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
35083000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14962000
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13588000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17195000
CY2019Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15874000
CY2019Q1 us-gaap Gross Profit
GrossProfit
16640000
CY2019Q2 us-gaap Gross Profit
GrossProfit
23071000
CY2019Q3 us-gaap Gross Profit
GrossProfit
25429000
CY2019Q4 us-gaap Gross Profit
GrossProfit
19209000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42972000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8597000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9874000
CY2019Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28720000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23647000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16977000
CY2019Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20420000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-64700000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-51779000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34853000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-59362000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1688000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1557000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1258000
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1442000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-63012000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-50222000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-33595000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-57920000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65

Files In Submission

Name View Source Status
0001564590-21-007841-index-headers.html Edgar Link pending
0001564590-21-007841-index.html Edgar Link pending
0001564590-21-007841.txt Edgar Link pending
0001564590-21-007841-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gtd3occ5wzks000001.jpg Edgar Link pending
hrtx-10k_20201231.htm Edgar Link pending
hrtx-10k_20201231_htm.xml Edgar Link completed
hrtx-20201231.xsd Edgar Link pending
hrtx-20201231_cal.xml Edgar Link unprocessable
hrtx-20201231_def.xml Edgar Link unprocessable
hrtx-20201231_lab.xml Edgar Link unprocessable
hrtx-20201231_pre.xml Edgar Link unprocessable
hrtx-ex231_10.htm Edgar Link pending
hrtx-ex311_6.htm Edgar Link pending
hrtx-ex312_8.htm Edgar Link pending
hrtx-ex321_7.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending